| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Wellgistics Health, Inc. Common Stock$3.12
+0.01 (+0.28%)
Market Cap
12.58 M
EPS
-1.29
P/E Ratio
-0.09 $
Value Trade
253.36 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.56 M
Operating CF
-3.41 M
Total Assets
30.13 M
Total Liabilities
45.19 M
Equity
-15.06 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
51.73 K
Monthly Burn
1.14 M
Runway
0 mo
Burn Trend
SEC Filing
May 19, 2026
Overview
Volume
21.59 K
52 Week Range
0.10 - 7.04
% held by Insiders
59.15 %
% held by Institutions
2.82 %
Enterprise Value
37.31 M
Total Shares
120.25 M
Short %
0.8 %
Float Shares
55.92 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in WGRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
WGRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
WGRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
WGRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
WGRX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
WGRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-WGRX
May 28, 2026Wellgistics Health Announces Lock-Up Agreement with Holders of a Majority of its Common Stock Holders of 1,333,930 common shares agree to minimum 90-day lock-up agreement TAMPA, FL
Wellgistics Health, Inc. has announced that holders of 1,333,930 common shares have agreed to a lock-up for at least 90 days, indicating strong shareholder confidence. The Interim Co-CEO stated that this agreement, along with recent financial restructuring, underscores the commitment to a vertically-integrated growth plan. Wellgistics aims to achieve significant milestones in the coming months, with plans to update the market about their progress.
Read more →-WGRX
May 21, 2026Wellgistics Health Releases Letter to Our Shareholders Why Vertical Integration and Blockchain Will Define the Next Era of Healthcare TAMPA, FL .-(BUSINESS WIRE)
Wellgistics Health has released a letter to shareholders outlining its strategy to utilize vertical integration and blockchain technology as foundational pillars for future healthcare improvements. The company believes that these approaches will enhance efficiency and trust across the entire healthcare system by consolidating fragmented data and workflows. Additionally, Wellgistics is integrating its AI platform, EinsteinRx, with blockchain capabilities to optimize prescription dispensing and improve patient engagement. The company's recent transactions are seen as critical steps in establishing itself as a central player in the healthcare infrastructure of the next decade.
Read more →-WGRX
May 20, 2026Wellgistics Health Announces Reverse Stock Split TAMPA, FL
Wellgistics Health, Inc. has announced a 1-for-50 reverse stock split aimed at regaining compliance with the Nasdaq Capital Market's minimum bid price requirement. The decision was approved by shareholders and will take effect at 12:01 a.m. on May 26, 2026. This move is part of a broader strategy to enhance the company’s stock value, reducing the number of outstanding shares significantly. The company also highlights its role as a leader in health information technology, optimizing prescription dispensing through its AI and blockchain technologies.
Read more →-WGRX
May 19, 2026Wellgistics Health Reports First Quarter 2026 Financials and Provides Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on
Wellgistics Health, Inc. (NASDAQ: WGRX) reported impressive financial results for the first quarter of 2026, highlighting a substantial increase in Wellgistics Pharmacy's monthly revenue. The company aims to capitalize on this growth by integrating innovative technologies and expanding its telepharmacy services through its partnerships, particularly with Kare Pharmtech and Tollo Health. However, the firm also recorded a notable operating loss of $7.742 million during the quarter, although this represents a significant reduction compared to the previous year.
Read more →-WGRX
May 19, 2026Wellgistics Health to Announce First Quarter 2026 Financials on Tuesday
Wellgistics Health, Inc. announced it will report its financial results for the first quarter of 2026 on May 19, 2026. The company is known for its healthcare technology solutions and aims to optimize the prescription drug dispensing process through its proprietary platforms. Wellgistics integrates pharmacy services with advanced technologies such as artificial intelligence and blockchain, serving a network of over 6,500 pharmacies. The announcement comes amidst forward-looking statements regarding potential acquisitions and the integration of new technologies.
Read more →-WGRX
Apr 14, 2026Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations Integrated platform acceler
Wellgistics Health, Inc. has entered a joint venture with Kare PharmTech's KareRx Hub to combine their technology platforms aimed at enhancing pharmaceutical access. This collaboration seeks to streamline the prescription journey for over 200,000 patients by integrating operational teams and service offerings of both companies. The joint venture is poised to leverage AI-driven insights and a comprehensive operational framework, although the specifics regarding timing and successful integration of the operations are yet to be confirmed.
Read more →-WGRX
Mar 11, 2026Wellgistics Strengthens PharmacyChain with Insurance Eligibility & Benefits Verification Capabilities Medical insurance eligibility and benefits verification is a core health technology capability necessary for PharmacyC
Wellgistics Health, Inc. announced the integration of insurance eligibility and benefits verification (EBV) capabilities into its PharmacyChain platform, aiming to enhance market adoption and streamline healthcare operations. The company secured preferential pricing for these services, which will enable providers to access essential information regarding patient coverage. Expected growth in the EBV market from $2.39 billion in 2025 to $3 billion by 2030 suggests significant revenue potential for Wellgistics. The enhancement aligns with the company's larger strategy to optimize the prescription drug dispensing process using AI technologies.
Read more →-WGRX
Mar 9, 2026Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 2030 1 Proprietary Forzet formulation provides pharmacis
Wellgistics Health, Inc. has launched Forzet, a medical food aimed at addressing muscle loss associated with GLP-1 agonist therapies such as Ozempic and Wegovy. The product is designed for diet management under physician supervision and is expected to cater to the growing GLP-1 agonist market, which is forecasted to expand from $70 billion in 2025 to $201 billion by 2030. Despite its potential, Forzet is not FDA-approved, which may affect its market penetration. The company plans to integrate it within their pharmacy network and telehealth solutions.
Read more →-WGRX
Feb 11, 2026Wellgistics Health to Add Telehealth & Mental Health AI Capabilities via Tollo Health Partnership Expansion Tollo Health recently formed subsidiary TolloCare, LLC ( TolloCare') initially targeted to provide telehealth se
Wellgistics Health (NASDAQ: WGRX) has announced an expansion of its partnership with Tollo Health to include telehealth services through its new subsidiary, TolloCare, LLC. This initiative targets GLP-1 and Long COVID patients while also integrating mental health solutions via a partnership with a San Francisco-based AI start-up. The move reflects Wellgistics' strategy to evolve from solely pharmaceutical distribution to a more comprehensive patient service model, maximizing healthcare accessibility and outcomes. The partnership seeks to bolster the company's Wellgistics Pharmacy Network with innovative telemedicine strategies.
Read more →-WGRX
Feb 3, 2026NFL Alumni Health Partners with Wellgistics Health to Deploy Technology to Improve Health Outcomes for Former NFL Players and Rural Communities Wellgistics Health to leverage EinsteinRx AI pharmacy hub and PharmacyChain
Wellgistics Health has partnered with NFL Alumni Health to deploy technology aimed at improving health outcomes for former NFL players and rural communities. The initiative will utilize Wellgistics' EinsteinRx AI pharmacy hub and PharmacyChain smart contracts to enhance healthcare access and effectiveness. Initial focus areas include mental health, weight loss, sleep apnea, and other critical health issues. The partnership is also supported by NFL Alumni Health Ambassadors to foster healthcare engagement in local communities.
Read more →-WGRX
Jan 7, 2026Wellgistics Health Provides 2026 Corporate Outlook Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx into pharmacy client point-of-sales systems has commenced EinsteinRx
Wellgistics Health has announced its 2026 corporate outlook, focusing on the integration of its AI platform EinsteinRx into pharmacy point-of-sale systems. This integration aims to reduce onboarding friction and enhance implementation efficiency while expanding its pharmacy network. By the end of 2026, Wellgistics plans to onboard 500 pharmacies per month. The company is also targeting improvement in supplier relationships for diabetes and related health conditions to further enhance service delivery.
Read more →-WGRX
Dec 19, 2025Wellgistics Health Reminds Shareholders of
Wellgistics Health, Inc. has announced a record date of December 19, 2025, for shareholders to receive Dream Bowl 2026 Meme Coin tokens. Shareholders will get one token for each share of common stock held. The company is integrating advanced technology into its operations, focusing on enhancing the efficiency of pharmacy dispensing. However, the tokens will not represent equity or have guaranteed value, as they do not confer ownership rights.
Read more →-WGRX
Dec 8, 2025Wellgistics Health Announces Launch of Diabetes Drug Brenzavvy to Wellgistics Pharmacy Network Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are unins
Wellgistics Health has launched its diabetes drug Brenzavvy through the Wellgistics Pharmacy Network, targeting the $16 billion SGLT-2 inhibitor market. This drug aims to provide better access and lower costs for the 33 million Americans with type II diabetes, particularly those who are uninsured or underinsured. The integration of the EinsteinRx AI platform will assist pharmacists in educating providers on Brenzavvy's advantages over competitors. This initiative represents a new model for next-generation drugs to facilitate broader market access and enhanced patient care.
Read more →-WGRX
Dec 3, 2025Wellgistics Health Announces that it will Distribute a Dream Bowl 2026 Meme Coin to Wellgistics Health Stockholders TAMPA, FL
Wellgistics Health, Inc. (WGRX) has announced that it will distribute a Dream Bowl 2026 Meme Coin to its stockholders, with a record date set for December 19, 2025. Shareholders will receive one meme coin for each share of common stock they own. The Dream Bowl 2026 event is slated for January 11, 2026, and aims to provide a large-scale platform for e-sports and athletic competitions. Detailed instructions for stockholders on how to register and set up digital wallets for the coin will be provided prior to the distribution date.
Read more →-WGRX
Nov 26, 2025Wellgistics Health Announces Sponsorship of Dream Bowl 2026 and Participation in DataVault AI Dream Bowl 2026 Meme Coin Shareholder Distribution Plan Company plans to distribute Dream Bowl 2026 Meme Coin to shareholders
Wellgistics Health, Inc. announced its sponsorship of the Dream Bowl 2026 event and participation in the DataVault AI Shareholder Distribution Plan for a new digital collectible, the Dream Bowl 2026 Meme Coin. Scheduled for January 11, 2026, at AT&T Stadium in Dallas, Texas, the event will feature elite athletes competing for the championship. Shareholders are set to receive airdropped Meme Coins, which are intended for personal use and do not confer any ownership rights or monetary benefits. Detailed distribution information will be provided to Wellgistics shareholders in December 2025.
Read more →-WGRX
Nov 25, 2025Datavault AI Licenses Patents Covering Digital Ledger-enabled Smart Contracts for Commercial Prescription Drug Distribution Industry to Wellgistics Health Exclusive licensing arrangement positions Wellgistics to become t
Datavault AI has announced an exclusive licensing arrangement with Wellgistics Health to utilize its smart contract technology in the prescription drug distribution sector. This partnership aims to optimize medication delivery through Wellgistics' PharmacyChain and the EinsteinRx AI hub. The collaboration is expected to enhance efficiency and reduce administrative burdens in the $634 billion medication market. Wellgistics aims to lead the digital transformation in healthcare, improving outcomes and lowering drug prices.
Read more →-WGRX
Nov 25, 2025DataVault AI Completes Exclusive License of Patents Covering Use of Blockchain-enabled Smart Contracts for Commercial Prescription Drug Distribution Industry to Wellgistics Health PharmacyChain Health Data Railroad' Part
DataVault AI has completed an exclusive licensing agreement with Wellgistics Health, enabling the latter to utilize patents related to blockchain-enabled smart contracts within prescription drug distribution. This partnership is intended to modernize the industry by optimizing workflows and enhancing transparency and efficiency. Wellgistics aims to integrate its proprietary artificial intelligence platform, EinsteinRx, into its existing infrastructure, leveraging over 6,500 pharmacies across the U.S. The move is expected to disrupt the current distribution model, reducing costs and improving outcomes for various stakeholders, including manufacturers and patients.
Read more →-WGRX
Nov 20, 2025Wellgistics Health Reports Third Quarter 2025 Financial Results and Provides Business Update TAMPA, FL
Wellgistics Health, Inc. has reported its financial results for the third quarter of 2025, highlighting a substantial net operating loss largely due to stock-based compensation. The company is focused on launching Brenzavvy for Type 2 diabetes while making strides with its EinsteinRx platform. However, risks include a significant increase in net losses compared to last year and the cancellation of a proposed acquisition that no longer aligns with strategic objectives. The outlook remains cautious as the company works to implement its technology and expand its offerings in a competitive market.
Read more →-WGRX
Oct 27, 2025Wellgistics Health Enters into Smart Contract Services Agreement with DataVault AI to Develop Patented PharmacyChain Manufacturer-to-Patient Blockchain-enabled Tracking & Dispensing Platform for Prescription Drug Market
Wellgistics Health has entered into a software as a service agreement with DataVault AI to develop a blockchain-enabled tracking and dispensing platform for the prescription drug market, named PharmacyChain. This platform aims to optimize pharmaceutical distribution by securely allowing data exchange between pharmacies and manufacturers. The beta testing for the platform is projected to commence in early 2026, reflecting the companies' commitment to innovation in this sector. Wellgistics' strategy focuses on utilizing smart contracts to enhance their service offerings and market position.
Read more →-WGRX
Oct 22, 2025DataVault AI and Wellgistics Health Announce Plans for PharmacyChain to Implement Manufacturer-to-Patient Blockchain-enabled Smart Contracts for the Prescription Drug Industry to Improve Efficiency and Patient Outcomes S
DataVault AI and Wellgistics Health are collaborating to implement blockchain-enabled smart contracts in the prescription drug industry. This partnership aims to enhance efficiency, transparency, and patient outcomes within the $634 billion U.S. market. The initiative includes using AI for optimizing prescription services and ensuring compliance with healthcare standards. However, the partnership is contingent upon the successful negotiation of agreements, which poses a risk to the realization of its benefits.
Read more →-WGRX
Oct 13, 2025Wellgistics Health Announces Executive Management and Board Changes TAMPA, FL
Wellgistics Health, Inc. announced significant management changes, including the re-appointment of Prashant Patel as President and Interim-CEO, while Eric Sherb takes on the role of Interim-CFO. Several board members have been appointed, but the company also saw the departure of its CEO, CFO, and COO, raising questions about leadership stability. Patel aims to streamline operations and create new revenue opportunities within the pharmaceutical distribution sector as the company adjusts its strategy.
Read more →-WGRX
Sep 25, 2025Wellgistics Health Announces Pricing of $5 Million Public Offering Thursday, 25 September 2025 08:01 PM Topic: Company Update TAMPA, FL / ACCESS Newswire /
Wellgistics Health, Inc. has announced the pricing of a public offering of 7,142,862 shares of common stock at $0.70 per share, including warrants. The offering is expected to raise approximately $5 million in gross proceeds, which the company intends to utilize for working capital, general corporate purposes, and growth initiatives. The effective registration statement by the SEC allows the company to proceed with the offering, slated to close around September 29, 2025. This move positions Wellgistics Health for future opportunities in pharmaceutical distribution and related services.
Read more →-WGRX
Sep 5, 2025Wellgistics Health, Inc. to Present at September Investor Conferences Friday, 05 September 2025 08:30 AM Topic: Conferences TAMPA, FL / ACCESS Newswire /
Wellgistics Health, Inc. (NASDAQ:WGRX) will participate in three investor conferences in September 2025, including the H.C. Wainwright Annual Global Investment Conference. CEO Brian Norton and his executive team aim to highlight the company’s innovations in pharmaceutical distribution and AI-powered fulfillment. These conferences present opportunities to engage with current and potential shareholders, emphasizing Wellgistics Health's strategic vision and operational capabilities.
Read more →-WGRX
Aug 27, 2025Wellgistics Health Introduces HubRx AI: Advancing the AI-Powered Prescription Ecosystem TAMPA, FL / ACCESS Newswire /
Wellgistics Health, Inc. has announced the launch of HubRx AI, a customizable AI platform designed to enhance prescription hub services and optimize patient care. This initiative aims to streamline processes such as patient onboarding, eligibility verification, and claims management while ensuring strict data privacy compliance. With the U.S. prescription drug market exceeding $800 billion and the pharmaceutical hub services market projected to grow significantly, Wellgistics Health aims to position itself as a leader through innovative AI solutions. Full implementation of HubRx AI is expected in late 2025, aiming for improved efficiency in the healthcare sector.
Read more →-WGRX
Aug 20, 2025Wellgistics Health Achieves Stability in First-Half 2025 and Executes Growth Initiatives TAMPA, FLORIDA / ACCESS Newswire /
Wellgistics Health, Inc. announced positive financial results for the second quarter ending June 30, 2025, reflecting an increase in revenue to $18.65 million. The company is undergoing significant organizational changes, including consolidation and debt reduction to enhance operational efficiency. Wellgistics also continues to expand its partnerships with pharmacies and manufacturers, aiming to strengthen its position in direct-to-patient delivery models. Leadership is focused on leveraging technology to facilitate faster and more affordable medication access for patients.
Read more →-WGRX
Aug 13, 2025Wellgistics Health (NASDAQ: WGRX) Launches XRP Payment Program for Independent Pharmacies TAMPA, FLORIDA / ACCESS Newswire /
Wellgistics Health (NASDAQ: WGRX) has launched an XRP Payment Program designed to facilitate blockchain-based payments for independent pharmacies. This initiative promises instant payment settlements, reduced fees, and improved cash flow adjustments for pharmacies by directly connecting them to product distributors. The program is built in partnership with RxERP and aims to enhance operational efficiency while ensuring compliance with healthcare regulations. As one of the first healthcare companies to adopt this solution, Wellgistics is poised to revolutionize financial transactions within the pharmaceutical supply chain.
Read more →-WGRX
Jul 25, 2025Wellgistics Health Converts $8.1M Debt to Equity TAMPA, FLORIDA / ACCESS Newswire /
Wellgistics Health, Inc. (NASDAQ: WGRX) announced the approval of an $8.1 million debt-to-equity conversion by its Board of Directors. This strategic move is aimed at strengthening the company's balance sheet by reducing short-term debt and is expected to enhance cash flow, improve access to capital, and facilitate the acquisition of pharmaceutical products. The company looks forward to expanding its network and advancing its technology platform, benefiting independent pharmacies and their operations in the prescription drug marketplace.
Read more →-WGRX
Apr 15, 2025CEO of Wellgistics Health Converts $1.5 Million of Debt to Equity at IPO Price TAMPA, FL / ACCESS Newswire /
Wellgistics Health, Inc. (NASDAQ:WGRX) has converted $1.5 million of debt into equity by issuing shares at its IPO price of $4.50. This transaction indicates CEO Brian Norton's confidence in the company's strategic direction, represented by a lock-up agreement on the newly issued shares. The company aims to innovate in healthcare technology and services, offering integrated solutions for various stakeholders in the pharmaceutical sector. This development is seen as a positive step toward fostering long-term shareholder value.
Read more →-WGRX
Apr 10, 2025Wellgistics Health, Inc. Announces Agreement to Acquire Peek Healthcare Technologies, Inc., to support over 2,500 patients and $1.5MM annual Revenue. TAMPA, FL
Wellgistics Health, Inc. has announced a definitive agreement to acquire Peek Healthcare Technologies, Inc., which operates a digital prescription shopping platform. This acquisition aims to enhance Wellgistics Health's offerings in patient-centric and transparent healthcare technology, supporting over 2,500 patients and generating an expected $1.5 million in annual revenue. The integration of Peek's services is anticipated to be immediately beneficial to earnings and broaden Wellgistics' market reach. Additionally, Peek will maintain its brand identity as it becomes a wholly-owned subsidiary of Wellgistics Health, further enhancing its capabilities in the pharmaceutical market.
Read more →-WGRX
Mar 27, 2025Wellgistics Health Annual Letter to Shareholders From the Office of the CEO March 2025 TAMPA, FL
Wellgistics Health, now publicly traded, has reported substantial growth with a projected increase in net sales for 2024 following several key acquisitions. The company is focusing on enhancing prescription access through innovative AI frameworks like Wellgistics Hub and EinsteinRx, designed to streamline the prescription process and improve patient engagement. However, challenges remain in the form of pricing pressures on pharmacies and ongoing issues with the transparency and efficiency of the healthcare system. The letter underscores a commitment to redefining pharmaceutical access while acknowledging the systemic hurdles in the industry.
Read more →-WGRX
Mar 18, 2025Wellgistics Health Achieves SOC 2 Type 1 Compliance, Strengthening Security for AI-Driven Pharmacy Solutions and Employer-Based Healthcare Models TAMPA, FL
Wellgistics Health, Inc. has announced its successful achievement of SOC 2 Type 1 compliance, affirming that it meets stringent security, availability, and privacy standards for its AI-driven pharmacy solutions. This certification, obtained through a third-party audit by Sensiba LLP, recognizes the company's strong commitment to safeguarding sensitive healthcare data. The compliance is indicative of Wellgistics Health's robust security framework designed to support its healthcare partners. The company aims to continue evolving as a trusted provider of technology solutions in the pharmacy industry.
Read more →-WGRX
Mar 4, 2025Protega Pharmaceuticals collaborates with Wellgistics to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND ROXYBOND, formulated
Protega Pharmaceuticals is collaborating with Wellgistics LLC to enhance pharmacist education and increase patient access to ROXYBOND, the first FDA-approved abuse-deterrent immediate-release opioid. This partnership seeks to provide resources and guidelines that promote responsible opioid prescribing and distribution. The initiative targets independent pharmacies, especially in underserved areas, emphasizing education on safe pain management and compliance. The collaboration represents a significant step in improving public health concerning opioid use and abuse deterrence.
Read more →-WGRX
Feb 26, 2025Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Market
Wellgistics Health, Inc. announced a partnership with Tollo Health, LLC to market innovative medical food products targeting GLP-1 treatment side effects and Long COVID. Tollo's products aim to address issues like muscle loss and gut discomfort, which are common among users of GLP-1 drugs. This collaboration aims to improve patient outcomes and expand healthcare support, as there are currently no approved prescription treatments available for these conditions. The GLP-1 drug market is projected to grow significantly, presenting a strong opportunity for Wellgistics and Tollo in the evolving healthcare landscape.
Read more →-WGRX
Feb 21, 2025Wellgistics Health, Inc. Announces Pricing of $4.0 Million Initial Public Offering Tampa, Florida
Wellgistics Health, Inc. has announced the pricing of its initial public offering (IPO) at $4.5 per share, aiming to raise approximately $4.0 million. The shares will be listed on the Nasdaq Capital Market under the ticker symbol 'WGRX', with trading expected to commence on February 21, 2025. The capital raised from the IPO is intended for general corporate purposes including marketing initiatives and working capital. However, the IPO's completion remains subject to standard market conditions.
Read more →Competitive Position
How WGRX ranks across every disease it competes inCompetitive Position is a premium feature
See how WGRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial